The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab

L. Tran, J. W. Baars, J. P. De Boer, C. A. Hoefnagel, J. H. Beijnen, A. D.R. Huitema

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

3 Citaten (Scopus)

Samenvatting

Purpose: To report the pharmacokinetics of 131I-rituximab a patient with a CD20 positive non-Hodgkin Lymphoma who has received 131I-rituximab as consolidation treatment after remission induction and to evaluate the effect of radioiodination on the biological properties of rituximab. Results: The patient was a 65-year-old male with a relapsed CD20 positive follicular non-Hodgkin Lymphoma. After induction therapy the patient was in partial remission. Following administration of a diagnostic dose of 185 MBq 131I-rituximab, remaining lesions were identified on the wholebody scans. The patient then received a therapeutic dose of 1000 MBq 131I-rituximab. The uptake by the tumor in the right axilla was 0.17-0.21% of the injected dose. The calculated biological half-life of 131I-rituximab was 684 hrs. This biological half-life corresponded well with the half-life of unlabeled rituximab which was approximately 720 hrs. Discussion and conclusion: Even though radioiodination of rituximab results in a reduced binding capacity, whole body scans demonstrated localization of 131I-rituximab in the tumor area. This observation supports the specific targeting of 131I-rituximab. The half-life of 131I-rituximab corresponded to the half-life of unlabeled rituximab. Hence, the pharmacokinetics of 131I-rituximab was not relevantly affected by the radioiodination process.

Originele taal-2Engels
Pagina's (van-tot)37-40
Aantal pagina's4
TijdschriftHuman Antibodies
Volume20
Nummer van het tijdschrift1-2
DOI's
StatusGepubliceerd - 2011
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'The pharmacokinetics of 131I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab'. Samen vormen ze een unieke vingerafdruk.

Citeer dit